Zacks Investment Research cut shares of Repligen (NASDAQ:RGEN) from a buy rating to a hold rating in a research report report published on Thursday morning.
According to Zacks, “Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. “
A number of other equities analysts have also weighed in on RGEN. BidaskClub upgraded shares of Repligen from a buy rating to a strong-buy rating in a research report on Friday, August 24th. JPMorgan Chase & Co. increased their target price on shares of Repligen to $60.00 and gave the stock an overweight rating in a research report on Monday, September 24th. HC Wainwright initiated coverage on shares of Repligen in a research report on Wednesday, September 26th. They set a neutral rating and a $49.00 target price for the company. Janney Montgomery Scott reiterated a buy rating on shares of Repligen in a research report on Thursday, October 4th. Finally, ValuEngine upgraded shares of Repligen from a buy rating to a strong-buy rating in a research report on Tuesday, October 23rd. Four analysts have rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $62.60.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $49.53 million during the quarter, compared to analyst estimates of $46.69 million. Repligen had a net margin of 12.61% and a return on equity of 5.39%. The company’s quarterly revenue was up 35.4% on a year-over-year basis. During the same quarter last year, the business earned $0.15 earnings per share. On average, sell-side analysts expect that Repligen will post 0.73 EPS for the current fiscal year.
In other news, CFO Jon Snodgres sold 31,753 shares of the firm’s stock in a transaction that occurred on Monday, November 26th. The shares were sold at an average price of $63.49, for a total value of $2,015,997.97. Following the completion of the transaction, the chief financial officer now directly owns 32,344 shares in the company, valued at $2,053,520.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 1,763 shares of the firm’s stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $65.75, for a total transaction of $115,917.25. Following the completion of the transaction, the director now owns 3,225 shares of the company’s stock, valued at $212,043.75. The disclosure for this sale can be found here. Insiders sold 61,082 shares of company stock valued at $3,722,749 over the last 90 days. 1.40% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the company. Smith Asset Management Group LP boosted its position in shares of Repligen by 1,511.8% in the second quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 4,369 shares during the period. Brown Advisory Inc. raised its stake in Repligen by 24.0% in the second quarter. Brown Advisory Inc. now owns 8,640 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 1,673 shares in the last quarter. American Capital Management Inc. purchased a new stake in Repligen in the third quarter valued at approximately $3,866,000. Aperio Group LLC raised its stake in Repligen by 5.5% in the third quarter. Aperio Group LLC now owns 44,515 shares of the biotechnology company’s stock valued at $2,469,000 after purchasing an additional 2,319 shares in the last quarter. Finally, Granahan Investment Management Inc. MA raised its stake in Repligen by 12.1% in the second quarter. Granahan Investment Management Inc. MA now owns 178,159 shares of the biotechnology company’s stock valued at $8,381,000 after purchasing an additional 19,230 shares in the last quarter. Institutional investors own 92.08% of the company’s stock.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Recommended Story: What is the NASDAQ Stock Market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.